Posts

Posted on

First Horizon Chief Human Resources Officer Tanya Hart Named a 2025 Woman of Impact by American Heart Association

PR Newswire


MEMPHIS, Tenn.
, Sept. 15, 2025 /PRNewswire/ — First Horizon Corporation is pleased to announce that Tanya Hart, Chief Human Resources Officer, has been named a 2025 Woman of Impact by the MidSouth Chapter of the American Heart Association.

The Woman of Impact program elevates the importance of women’s health, recognizing that cardiovascular disease remains the leading cause of death among women. Nominees directly improve the health of their communities by championing efforts like CPR education, promoting mental well-being and advancing policies that save lives.

As part of a distinguished local cohort of ten women, Hart helped raise more than $200,000 in just nine weeks. Hart finished in the top three, demonstrating her commitment to meaningful change and drive to make a difference.

“Tanya’s recognition is a wonderful testament to her commitment and to the spirit of service shared by all our associates,” said Bryan Jordan, Chairman, President and CEO of First Horizon. “We are proud to support programs that elevate the health and vitality of our clients and communities.”

Hart has been recognized as a 2025 Super Woman in Business by the Memphis Business Journal and one of the 2024 Savoy Magazine Most Influential Executives in Corporate America. In addition, she is actively involved with a variety of civic and professional institutions across the Memphis region. Her community outreach includes her role as a board member, treasurer and chair of the Nomination and Governance Committee of the University of Memphis Foundation Board, and secretary and executive member of  the Brooks Museum of Art.

About First Horizon 

First Horizon Corporation (NYSE: FHN), with $82.1 billion in assets as of June 30, 2025, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation’s best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/first-horizon-chief-human-resources-officer-tanya-hart-named-a-2025-woman-of-impact-by-american-heart-association-302556912.html

SOURCE First Horizon Corporation

Posted on

Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

HENDERSON, Nev.–(BUSINESS WIRE)–
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today posted the following summary notice of pendency and proposed settlement of stockholder derivative actions.

To: All Record Holders and Beneficial Owners of Paysign, Inc. (“Paysign” of the “Company”) Common Stock as of November 25, 2024.

Please read this summary notice carefully and in its entirety and as your rights may be affected by proceedings in the litigation.

YOU ARE HEREBY NOTIFIED that the following stockholder derivative actions (the “Derivative Actions”), are being settled on the terms set forth in a Stipulation and Agreement of Settlement dated November 25, 2024 (the “Stipulation”): (i) the above-captioned consolidated action, titled Toczek v. Newcomer et al, Case No. 2:20-cv-01722-JCM-NJK; (ii) Blanchette v. Paysign, Inc. et al., Case No. 2:23-cv-01632-JCM-BNW (D. Nev.); and (iii) Jeewa v. Newcomer, et al., Case No. 2:23-cv-02129-RFB-EJY (D. Nev.).

The Derivative Actions allege that, inter alia, between March 12, 2019 through September 17, 2020, at least, the Individual Defendants breached their fiduciary duties by issuing and/or causing the Company to issue materially false and misleading statements (including by soliciting a materially false and misleading proxy statement allegedly in violation of Section 14(a) of the Securities Exchange Act of 1934) and by failing to disclose material facts to the public regarding, among other things, that: (1) the Company failed to design, implement, and maintain effective IT general controls, specifically pertaining to user access and the Company’s systems change management; (2) the Company failed to maintain effective disclosure controls and internal controls over its financial reporting; and (3) due to the foregoing, the Company would be forced to delay filing its 2019 10-K and holding its 2019 year-end earnings call. The Derivative Actions also allege that the Individual Defendants breached their fiduciary duties by failing to correct and/or causing the Company to fail to correct these false and misleading statements and omissions of material fact to the investing public, while four of the Individual Defendants engaged in lucrative insider sales, netting combined proceeds of over $5.7 million. The Derivative Actions allege that, as a result of the foregoing, the Company experienced reputational and financial harm. Defendants have denied and continue to deny each and all of the claims and allegations of wrongdoing asserted in the Derivative Actions.

Pursuant to the terms of the Settlement, Paysign agrees to implement and maintain certain corporate governance reforms that are outlined in Exhibit A to the Stipulation (the “Reforms”). The Reforms shall be maintained for five (5) years. Paysign acknowledges and agrees that the filing, pendency, and settlement of the Derivative Actions was the cause of the Company’s decision to adopt, implement, and maintain the Reforms. Paysign also acknowledges and agrees that the Reforms confer substantial benefits to Paysign and its shareholders.

After negotiating the principal terms of the Settlement, counsel for the Parties, with the assistance of the Mediator, negotiated the attorneys’ fees and expenses to be paid to Plaintiffs’ Counsel, subject to Court approval (the “Fee and Expense Amount”). In light of the substantial benefits conferred upon the Company and its stockholders, Defendants’ insurers shall pay to Plaintiffs’ Counsel $607,500.00 for their attorneys’ fees and expenses, subject to Court approval. Defendants also agreed not to object to the request for the Court to approve Service Awards of up to two thousand dollars ($2,000.00) for each of the four Plaintiffs, to be paid from the Fee and Expense Amount.

On November 14, 2025 at 1:00 p.m., a hearing (the “Settlement Hearing”) will be held before the Honorable Richard F. Boulware at the United States District Court for the District of Nevada, Las Vegas Division, 333 Las Vegas Boulevard South, Las Vegas, Nevada 89101, for the purpose of determining whether the Settlement should be approved as fair, reasonable, and adequate and whether the Court should approve the agreed-to Fee and Expense Amount and the Service Awards for Plaintiffs. Because this is not a class action, except as otherwise provided for in the Stipulation with respect to the Plaintiffs, no Current Paysign Stockholder has the right to receive any individual compensation as a result of the Settlement.

This Summary Notice provides a condensed overview of certain provisions of the Stipulation and the full Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions (the “Notice”). It is not a complete statement of the events of the Derivative Actions or the terms set forth in the Stipulation. This summary should be read in conjunction with, and is qualified in its entirety by reference to, the text of the Stipulation. For additional information about the claims asserted in the Derivative Actions, and the terms of the proposed Settlement, you may inspect the full Notice and the Stipulation and its exhibits and other papers at the Clerk’s office in the Court at any time during regular business hours. In addition, copies of the Stipulation and its exhibits and the Notice are available on the Investor Relations page of the Company’s website, www.paysign.com.

The Court may, in its discretion, change the date, time, or format of the Settlement Hearing without further notice to you. If you intend to attend the Settlement Hearing, please consult the Court’s calendar or Investor Relations page of the Company’s website, www.paysign.com, for any change in the date, time, or format of the Settlement Hearing.

Inquiries about the Derivative Actions or the Settlement may be made to: Timothy Brown, The Brown Law Firm, P.C., 767 Third Avenue, Suite 2501, New York, NY 10017, Telephone: (516) 922-5427, Email: [email protected].

You may enter an appearance before the Court, at your own expense, individually or through counsel of your choice. If you want to object at the Settlement Hearing, you must be a Current Paysign Stockholder and you must first comply with the procedures for objecting that are set forth in the Notice. Any objection to any aspect of the Settlement must be filed with the Clerk of the Court and sent to Plaintiffs’ Counsel and Defendants’ Counsel no later than October 24, 2025 (21 days before the Settlement Hearing), in accordance with the procedures set forth in the Stipulation and the Notice. Any Current Paysign Stockholder who fails to object in accordance with such procedures will be bound by the Order and Final Judgment of the Court granting final approval to the Settlement and the releases of claims therein, and shall be deemed to have waived the right to object (including the right to appeal) and forever shall be barred, in this proceeding or in any other proceeding, from raising such objection.

PLEASE DO NOT CALL THE COURT OR DEFENDANTS WITH QUESTIONS ABOUT THE SETTLEMENT.

About Paysign

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

Investor Relations

[email protected]

888.522.4853

paysign.com/investors

Media Relations

Alicia Ches

888.522.4850

[email protected]

KEYWORDS: United States North America Nevada

INDUSTRY KEYWORDS: Security Data Management Legal Technology Finance Consulting Fintech Pharmaceutical Practice Management Banking Professional Services Payments Software Data Analytics Health

MEDIA:

Logo
Logo
Posted on

/C O R R E C T I O N — Blue Water Acquisition Corp iii/

PR Newswire

In the news release, Blue Water Advances in CITGO Bidding Process, issued 15-Sep-2025 by Blue Water Acquisition Corp iii over PR Newswire, we are advised by the company that the media contact was omitted from the text. The complete, corrected release follows:

Blue Water Advances in CITGO Bidding Process


NEW YORK
, Sept. 15, 2025 /PRNewswire/ — Blue Water Venture Partners, LLC (“Blue Water”), an entity affiliated with Joeseph Hernandez, the Chairman and Chief Executive Officer of Blue Water Acquisition Corp. III (Nasdaq: “BLUWU”), announced today that it has received court approval to enter into a non-disclosure agreement with the Special Master, granting access to the confidential data room established for the CITGO sale.

Blue Water continues to assert that its proposal represents the most compelling and beneficial path forward for all stakeholders. Blue Water’s $10 billion bid surpasses existing offers and is purpose-built to safeguard U.S. energy security while ensuring fair and equitable treatment of creditors.

Key highlights of the Blue Water proposal include: 

  • Superior Valuation: A $10 billion offer that exceeds current bids under consideration. 
  • American Public Ownership: A commitment to transform CITGO into a publicly traded U.S. company, promoting transparency and broad market participation. 
  • Creditor Equity Conversion: Bondholders and creditors would gain the opportunity to own shares in a public company, subject to regulatory and shareholder approval, preserving long-term value.
  • Protecting U.S. Energy Security: The proposal intends to prevent private hedge funds or foreign companies from controlling critical American energy assets. 
  • Uninterrupted Supply to U.S. Markets: Ensures continued and stable energy delivery to U.S. consumers, with a focus on safeguarding the Midwest region.

“We believe our bid not only delivers the strongest value to creditors and bondholders, but also ensures CITGO remains a vital, majority American-owned energy provider that supports U.S. markets and consumers,” said Joseph Hernandez, Chairman of Blue Water Venture Partners. “Our vision is to return CITGO to the public markets in a way that protects energy independence, strengthens creditor recovery, and prevents hedge fund or foreign control over critical U.S. energy assets.”

Blue Water remains committed to active participation in the sale process and to working collaboratively with all stakeholders to achieve the best possible outcome for creditors, consumers, and the broader U.S. energy market.

About Blue Water Acquisition Corp. III

Blue Water Acquisition Corp. III (Nasdaq: BLUWU) is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with high-potential companies across diverse sectors.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties, including the outcome of the court-supervised auction process, regulatory approvals, and market conditions. Actual results may differ materially from those expressed or implied. Blue Water Acquisition Corp. III disclaims any obligation to update forward-looking statements except as required by law.  These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, including without limitation, Blue Water Acquisition Corp. III’s ability to enter into definitive agreements and complete the transaction. These risks, uncertainties and other factors are expected to be further described in a proxy statement/registration statement to be filed with the Securities and Exchange Commission (the “SEC”) relating to any business combination transaction.  

Participants in the Solicitation

Blue Water Acquisition Corp. III and its respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in a solicitation of its shareholders in connection with a proposed business combination. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of Blue Water Acquisition Corp. III directors and officers in its SEC filings. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Blue Water Acquisition Corp. III shareholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus for the proposed business combination when available. 

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Contact

Investor & Media Inquiries
Blue Water Venture Partners
[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blue-water-advances-in-citgo-bidding-process-302556842.html

SOURCE Blue Water Acquisition Corp iii

Posted on

Tronox Announces Pricing of $400 Million Aggregate Principal Amount of 9.125% Senior Secured Notes

PR Newswire


STAMFORD, Conn.
, Sept. 15, 2025 /PRNewswire/ — Tronox Holdings plc (NYSE: TROX) (“Tronox” or the “Company”) today announced that Tronox Incorporated (the “Issuer”), a wholly owned subsidiary of the Company, has priced its offering of $400 million aggregate principal amount of 9.125% Senior Secured Notes due 2030 (the “Notes”). The offering was made to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain persons in offshore transactions pursuant to Regulation S under the Securities Act. The closing of the offering is anticipated to take place on or about September 26, 2025, subject to customary closing conditions. The Notes were offered at par and will bear interest semiannually at a rate equal to 9.125%. The Notes will be fully and unconditionally guaranteed on a senior, secured basis by Tronox Holdings plc and certain of its subsidiaries.

The Company expects to use the net proceeds from this offering to repay existing borrowings under certain of the Company’s revolving credit facilities and to pay fees and expenses related to this offering, with any excess proceeds used for other general corporate purposes. 

The Notes and related guarantees will not be registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.

This announcement is neither an offer to sell nor a solicitation to buy any of the foregoing securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Tronox

Tronox Holdings plc is one of the world’s leading producers of high-quality titanium products, including titanium dioxide pigment, specialty-grade titanium dioxide products and high-purity titanium chemicals, and zircon. We mine titanium-bearing mineral sands and operate upgrading facilities that produce high-grade titanium feedstock materials, pig iron and other minerals, including the rare earth-bearing mineral, monazite. With approximately 6,500 employees across six continents, our rich diversity, unmatched vertical integration model, and unparalleled operational and technical expertise across the value chain, position Tronox as the preeminent titanium dioxide producer in the world.

Forward Looking Statements

Statements in this release that are not historical are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include, without limitation, statements regarding the intended conduct, timing and terms of the proposed Notes offering and any future actions by us in respect of the Notes offering. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results to differ materially from those expressed or implied by the forward-looking statements. Significant risks and uncertainties may relate to, but are not limited to, macroeconomic conditions; policy changes affecting international trade, including import/export restrictions and tariffs;  inflationary pressures and energy costs; currency movements; political instability, including the ongoing conflicts in Eastern Europe and the Middle East and any expansion of such conflicts, and other geopolitical events; supply chain disruptions; market conditions and price volatility for titanium dioxide, zircon and other feedstock materials, as well as global and regional economic downturns, that adversely affect the demand for our end-use products; disruptions in production at our mining and manufacturing facilities; and other financial, economic, competitive, environmental, political, legal and regulatory factors. These and other risk factors are discussed in the Company’s filings with the Securities and Exchange Commission.

Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can management assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, synergies or achievements. Neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Unless otherwise required by applicable laws, we undertake no obligation to update or revise any forward-looking statements, whether because of new information or future developments.

Investor Relations and Media Contact: Jennifer Guenther
+1.203.705.3701 extension: 103701 (Media)
+1.646.960.6598 (Investor Relations)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tronox-announces-pricing-of-400-million-aggregate-principal-amount-of-9-125-senior-secured-notes-302556885.html

SOURCE Tronox Holdings plc

Posted on

Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

MATAWAN, N.J.–(BUSINESS WIRE)–
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego’s Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry.

Future Labs is part of Apimeds’ ai² innovation platform, connecting university students with real-world strategy and business development projects. Through this collaboration, student teams will work closely with Apimeds mentors to identify and evaluate opportunities to advance development projects previously left behind by industry.

“We’re thrilled to welcome University of San Diego students into the Future Labs program,” said Erik Emerson, CEO of Apimeds. “USD represents exactly the type of forward-thinking institution we want to partner with—where students are encouraged to bring fresh perspectives to complex problems. Drug development is challenging, and many therapies with true potential never reach patients. Future Labs is meant to function as both a discovery engine for assets and a training ground for tomorrow’s leaders.”

Students will gain hands-on experience in market analysis, FDA regulations, clinical development requirements, competitive positioning, intellectual property, and commercialization planning—skills that extend far beyond the classroom. Top-performing teams at each participating institution will be eligible for paid internships or consulting opportunities with Apimeds, creating a direct pathway into the industry.

“As a recent graduate of the University of San Diego, I see Future Labs as an incredible way to take what we’ve learned in the classroom and apply it directly to the challenges of the biopharma industry,” said Coben Emerson, Manager, FP&A, Apimeds. “By working hands-on with asset evaluation and strategy, students not only contribute to Apimeds’ pipeline exploration but also gain the kind of practical, career-ready experience that sets us apart as we enter the workforce.”

“Our students will gain invaluable exposure to the business side of the life sciences industry,” said Jaime Alonso Gomez, PhD, professor of strategy, international management and family business at the Knauss School of Business. “Partnering with Apimeds allows us to deliver a one-of-a-kind experience—where academic rigor meets real-world biopharma decision-making.”

The initiative underscores Apimeds’ commitment to fostering innovation, building meaningful industry–academic collaborations, and shaping the next generation of biotech leaders.

About Apimeds Pharmaceuticals

Apimeds Pharmaceuticals (NYSE American: APUS) is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. The company’s lead product candidate, Apitox, is in late-stage clinical development for osteoarthritis of the knee. For more information visit www.apimedsus.com. Information on the Apimeds’ website does not constitute a part of and is not incorporated by reference into this press release.

About the Knauss School of Business, University of San Diego

The Knauss School of Business at the University of San Diego is committed to developing socially responsible leaders with a global mindset through values-based education and innovative research. Together, we work to advance sustainable and ethical business solutions that address the world’s greatest challenges.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Apimeds undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Apimeds will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the company or its business or operations. Readers are cautioned that certain important factors may affect Apimeds’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect Apimeds’ results include, but are not limited to, the ability of Apimeds to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to Apimeds’ ability to advance its product candidate and successfully complete clinical trials; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Apimeds’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on April 15, 2025 (as amended on May 2, 2025).

Media Contact:

Brian Peters

Apimeds Pharmaceuticals

919-602-6557

KEYWORDS: United States North America California New Jersey

INDUSTRY KEYWORDS: Science Other Science Biotechnology Research Pharmaceutical Health University Education

MEDIA:

Posted on

Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference

PR Newswire


SECAUCUS, N.J.
, Sept. 15, 2025 /PRNewswire/ — Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company’s strategy, performance and the latest market developments and trends during the Jefferies Healthcare Services Conference in Nashville on Monday, September 29, 2025, at 4:35 p.m. Eastern Time.

The fireside chat and Q&A session will be webcast live during the conference on the company’s investor relations page, which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until October 24, 2025.

About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world’s largest databases of de-identifiable clinical lab results, Quest’s diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-speak-at-the-jefferies-healthcare-services-conference-302556883.html

SOURCE Quest Diagnostics

Posted on

VFC Investors have Opportunity to Lead V.F. Corporation Securities Fraud Lawsuit

PR Newswire


NEW YORK
, Sept. 15, 2025 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of V.F. Corporation (NYSE: VFC) between October 30, 2023 and May 20, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2025.

So what: If you purchased V.F. Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of V.F. Corporation’s turnaround plans. Specifically, defendants provided investors with material information concerning V.F. Corporation’s turnaround plan (“Reinvent”), which in part focused on efforts to return the Vans brand to positive growth. The lawsuit alleges that defendants concealed that additional significant reset actions would be necessary to return the Vans brand to growth, and would result in significant setbacks to Vans’ revenue growth trajectory. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vfc-investors-have-opportunity-to-lead-vf-corporation-securities-fraud-lawsuit-302556876.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

USA Compression Partners, LP Announces Pricing of $750.0 Million Offering of Senior Notes

USA Compression Partners, LP Announces Pricing of $750.0 Million Offering of Senior Notes

DALLAS–(BUSINESS WIRE)–
USA Compression Partners, LP (NYSE: USAC) (the “Partnership”) today announced the pricing of a private placement to eligible purchasers by the Partnership and its wholly-owned subsidiary, USA Compression Finance Corp., of $750.0 million in aggregate principal amount of 6.250% senior unsecured notes due 2033 at par. The offering is expected to close on September 24, 2025, subject to customary closing conditions.

The Partnership estimates that it will receive net proceeds of approximately $742.5 million, after deducting the initial purchasers’ discounts and estimated offering expenses. The net proceeds from the offering, together with borrowings under its credit agreement, will be used for the redemption of all of its 6.875% senior notes due 2027 (the “Senior Notes 2027”) and to pay the fees and expenses incurred in connection with this offering and the redemption of the Senior Notes 2027. Pending the use of the net proceeds to fund a portion of the redemption of the Senior Notes 2027, the Partnership may temporarily apply such net proceeds to repay outstanding borrowings under its credit agreement.

The notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any other jurisdiction. Unless they are registered, the notes may be offered only in transactions that are exempt from registration under the Securities Act and applicable state securities laws. The notes are being offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act and to non-U.S. persons outside the United States under Regulation S of the Securities Act. The notes will not be listed on any securities exchange or automated quotation system.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offering may be made only by means of an offering memorandum. This press release is not a notice of redemption for the Senior Notes 2027.

FORWARD-LOOKING STATEMENTS

Statements in this press release may be forward-looking statements as defined under federal law, including those related to the Partnership’s securities offering. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors, many of which are outside the control of the Partnership, and a variety of risks that could cause results to differ materially from those expected by management of the Partnership. The Partnership undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release. Known material factors that could cause the Partnership’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the Partnership’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on February 11, 2025, and in the Partnership’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which was filed with the SEC on May 6, 2025. You should also understand that it is not possible to predict or identify all such factors and you should not consider these factors to be a complete statement of all potential risks and uncertainties.

USA Compression Partners, LP

Investor Relations

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Energy Other Manufacturing Manufacturing Oil/Gas

MEDIA:

Logo
Logo
Posted on

Microsoft announces quarterly dividend increase

PR Newswire

Annual shareholders meeting set for Dec. 5, 2025


REDMOND, Wash.
, Sept. 15, 2025 /PRNewswire/ — Microsoft Corp. on Monday announced that its board of directors declared a quarterly dividend of $0.91 per share, reflecting an 8 cent or 10% increase over the previous quarter’s dividend. The dividend is payable Dec. 11, 2025, to shareholders of record on Nov. 20, 2025. The ex-dividend date will be Nov. 20, 2025.

In addition, the company announced the date for the 2025 Annual Shareholders Meeting, to be held Dec. 5, 2025. Shareholders at the close of business on Sept. 30, 2025, the record date, will be entitled to vote their shares.

This year’s annual shareholders meeting will be held virtually and hosted by Satya Nadella, chairman and chief executive officer; Amy Hood, executive vice president and chief financial officer; Brad Smith, vice chair and president; and Sandra E. Peterson, Microsoft lead independent director.

Microsoft (Nasdaq “MSFT” @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI available broadly and doing so responsibly, with a mission to empower every person and every organization on the planet to achieve more.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/microsoft-announces-quarterly-dividend-increase-302556874.html

SOURCE Microsoft Corp.

Posted on

POLARIS RZR FACTORY RACE TEAM SECURES THIRD CONSECUTIVE VICTORY AT THE BAJA 400, CEMENTING OFF-ROAD RACING DOMINANCE

PR Newswire


Brock Heger, Cayden MacCachren, and Max Eddy Jr. Deliver Statement Finish With a UTV Overall Podium Sweep


MINNEAPOLIS
, Sept. 15, 2025 /PRNewswire/ — Polaris RZR Factory Racing has once again demonstrated its unparalleled superiority in desert racing, with a podium sweep and its third consecutive victory at the prestigious Baja 400. Led by race winner Brock Heger, the dominating performance and podium sweep was the team’s second consecutive sweep at SCORE series races and yet another powerful example of RZR Factory Racing’s dominance in the Pro UTV Open Class. 

Once again, it was Heger, setting the gold standard, piloting his RZR Pro R Factory through Baja’s grueling desert terrain to earn his third consecutive SCORE UTV overall victory and his fourth in the last four SCORE events. His win also marked a rare three-peat at the event for the RZR Factory Racing Team. Teammate Cayden MacCachren went back and forth with Heger through the first half of the race and finished second overall. Rounding out the sweep, Max Eddy Jr, locked in third overall and secured Polaris’ complete takeover of the UTV category.

The back-to-back podium sweeps reinforce the Polaris RZR Factory Team’s unmatched depth of talent and the race-proven engineering of the RZR Pro R Factory. Purpose built and intentionally engineered for desert racing, the Pro R Factory has quickly established itself as the premier machine in the sport, delivering durability, handling, and performance that set it apart from the competition.

“Wins like this are why we race,” said Alex Scheuerell, Director of Off-Road Motorsports, Polaris. “Our team refuses to settle and every time they hit the desert, they raise the bar higher. Sweeping the UTV Overall podium not once, but twice, is more than we could’ve asked for.. The RZR Pro R Factory isn’t just proving itself; it’s redefining what’s possible in desert racing. Huge credit goes to our Polaris RZR engineers and everyone at SCI, they build machines built to win, and today was proof of that.”

With starting positions based on the Baja 500 results, Brock Heger launched off the line first, followed by Cayden MacCachren, Max Eddy Jr. in sixth and Justin Morgan strategically starting last. Heger wasted no time putting the RZR Pro R Factory’s winning performance on full display.

Leveraging the Polaris RZR’s desert-racing design, maximum power, and unmatched handling, Heger surged to an early lead. Teammate Cayden MacCachren battled the terrain and momentarily took over the physical lead and corrected lead by RM 211. Both teammates piloted their RZR Pro R Factory machines over the grueling Baja 400 course with Heger taking control over MacCachren for the final 200 miles. Heger’s performance further cements his place as the sport’s most elite driver and showcased the RZR Pro R Factory as the vehicle to beat in the class.

Max Eddy Jr., starting sixth off the line, methodically navigated the technical and grueling Baja 400 course. By race mile 211, Eddy Jr. and his #1841 Polaris RZR Pro R Factory had moved into both physical and corrected third place. He performed flawlessly throughout the entire race, ultimately completing the UTV Overall podium sweep with a time of 9:36:42. Adding to the team’s strong showing, Justin Morgan executed a calculated strategy by starting at the back of the field and charging forward. His patience and precision paid off as he piloted his Polaris RZR Pro R Factory to an impressive ninth-place overall finish in the Pro UTV class.

“I’m incredibly proud to be part of Polaris and the RZR Factory Racing team,” said Heger. “The RZR Pro R Factory continues to amaze me with its performance and durability. From the engineers and race ops to support staff and teammates, everyone comes together to put us in a position to succeed, and it shows when we’re able to win in such commanding fashion and finish 1-2-3 overall.”

Next, the Polaris RZR Factory Racing team will begin preparation for the Baja 1000, November 10–16, 2025. Polaris and the RZR Factory Racing Team look to defend its Baja 1000 title, while Brock Heger is primed to win back-to-back SCORE Desert National Championships.

To learn more, please visit Polaris.com/RZR or join the conversation and follow on Facebook sm, Instagram sm, YouTube sm and Xsm.

About Polaris
As the global leader in powersports, Polaris Inc. (NYSE: PII) pioneers product breakthroughs and enriching experiences and services that have invited people to discover the joy of being outdoors since our founding in 1954. Polaris’ high-quality product line-up includes the RANGER, RZR and Polaris XPEDITION and GENERAL side-by-side off-road vehicles; Sportsman all-terrain off-road vehicles; military and commercial off-road vehicles; snowmobiles; Indian Motorcycle mid-size and heavyweight motorcycles; Slingshot moto-roadsters; Aixam quadricycles; Goupil electric vehicles; and pontoon and deck boats, including industry-leading Bennington pontoons. Polaris enhances the riding experience with a robust portfolio of parts, garments, and accessories. Headquartered in Minnesota, Polaris serves nearly 100 countries across the globe. www.polaris.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/polaris-rzr-factory-race-team-secures-third-consecutive-victory-at-the-baja-400-cementing-off-road-racing-dominance-302556865.html

SOURCE Polaris Inc.